Skip to main content
European Commission logo
Deutsch Deutsch
CORDIS - Forschungsergebnisse der EU
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Inhalt archiviert am 2024-06-18

Non-Radioactive Molecular Imaging-Driven Drug Development in Oncology

Ziel

Cancer is a leading cause of death worldwide. Fortunately an abundance of cancer drugs are becoming available; the challenge now is to select the most promising. Integrated cancer research and biomarker-driven adaptive and hypothesis-testing clinical trials are imperative. Many tumor characteristics can now be visualized simultaneously, but the necessary tracers have hardly been explored clinically. In the onQview program, we aim to create a drug development strategy based on a novel non-radioactive molecular imaging approach to guide patient-tailored selection of drugs, to measure in vivo drug and tumor behavior, and to allow dynamic treatment tuning. Our extensive (pre)clinical experience with molecular imaging and drug development is hereby merged with our unique infrastructure, including lasers, microscopes, and advanced detection systems for non-ionizing electromagnetic waves, for optical and photoacoustic imaging modalities. We will develop novel non-radioactive tracers based on HER-targeting drugs in breast and colon cancer, and use molecular imaging to track the drugs and corresponding effect sensors that visualize targeting effects. This approach will allow dynamic treatment tuning in pre-clinical (animal) experiments. We will also advance the implementation of optical and photoacoustic imaging with optimized measurement techniques and quantification strategies that will allow testing of the new tracers in breast/colon cancer models. Two tracers will be produced for human use and evaluated in clinical studies that enable visualization of drug behavior, drug targets and drug effects in relation to the HER family in breast and colon cancer.

Aufforderung zur Vorschlagseinreichung

ERC-2011-ADG_20110310
Andere Projekte für diesen Aufruf anzeigen

Gastgebende Einrichtung

ACADEMISCH ZIEKENHUIS GRONINGEN
EU-Beitrag
€ 1 797 749,40
Adresse
HANZEPLEIN 1
9713 GZ Groningen
Niederlande

Auf der Karte ansehen

Region
Noord-Nederland Groningen Overig Groningen
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Gerda G. Klooster (Dr.)
Hauptforscher
Emma Geertruida Elisabeth De Vries (Prof.)
Links
Gesamtkosten
Keine Daten

Begünstigte (2)